Tech Company Financing Transactions
Vigilant Biosciences Funding Round
On 7/11/2016, Vigilant Biosciences raised $5 million in Series B funding from private investors, venVelo and White Owl Capital.
Transaction Overview
Company Name
Announced On
7/11/2016
Transaction Type
Venture Equity
Amount
$5,000,000
Round
Series B
Investors
Proceeds Purpose
Vigilant expects to use the funds to support numerous commercial and development efforts, including the international commercialization of its OncAlert� Oral Cancer product line and the advancement of its OncAlert Labs product line. Additionally, the funds raised will support the continued research and development of additional products in Vigilant's pipeline.
Company Information
Company Status
Private & Independent
Industry
Medical Devices & Instruments
Mailing Address
6301 NW 5th Way 1500
Ft. Lauderdale, FL 33309
USA
Ft. Lauderdale, FL 33309
USA
Phone
Website
Email Address
Overview
Vigilant Biosciences is a leading innovator and developer of solutions that aid in the early detection and intervention of cancer.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
William Brodie
Chief Financial Officer
Robert Hamilton
Chief Medical Officer
Michael Donovan
Chief Scientific Officer
Elizabeth Franzmann
VP - Operations
Tony Lavecchia
VP - Regulatory Affairs
Kris Foss
Browse more venture capital transactions:
Prev: 7/8/2016: ZIOPHARM Oncology venture capital transaction
Next: 7/11/2016: CornerJob venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC investment data records on this site are sourced from publicly available VC deal announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs